Myc Expression And Tumor-Infiltrating T Cells Are Associated With Response In Patients (Pts) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl) Treated With Tisagenlecleucel In The Juliet Trial

Background: Tisagenlecleucel (tisa-cel; autologous anti-CD19 CAR-T cell therapy) has demonstrated durable responses and a manageable safety profile in adult pts with r/r DLBCL in the JULIET trial. Here we report updated efficacy results with a 40 month median follow-up and associations with baseline Myc overexpression in tumor and tumor microenvironment (TME) characteristics.